haloprogin (halotex) Report issue

Small molecule Approved FDA Priority Review FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Haloprogin is an active synthetic antifungal and antimonilial agent that was effective in the treatment of superficial fungal and monilial infections of the skin. Because of these two basic therapeutic effects, haloprogin was especially useful in the treatment of infections when the identity of the specific causative organism had not been established or is being determined. Studies in-vitro demonstrated antifungal, antimonilial and antibacterial activity. It was shown to demonstrate marked in-vitro activity against Staphylococcus and Streptococcus. Haloprogin is no longer available in the US.   NCATS

Chemistry

  • SMILES: ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
  • InChIKey: CTETYYAZBPJBHE-UHFFFAOYSA-N
  • Mol. Mass: 361.391
  • ALogP: 4.42
  • ChEMBL Molecule:
    haloprogin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Topical
  • Pro Drug: No

Alternative names

haloprogin | haloprogina | haloprogine | haloproginum | halotex | m-1028 | mycanden | mycilan | théraplix brand of haloprogin | westwood squibb brand of haloprogin

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (4)


 

Candidiasis, Cutaneous

Tinea

Tinea Pedis

Tinea Versicolor

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue